Consensus EyePoint, Inc.

Stocks

EYPT

US30233G2093

Pharmaceuticals

Market Closed - Nasdaq 01:30:00 31/10/2026 am IST			5-day change	1st Jan Change
0.3484 ^USD	-8.32%		-13.87%	-98.09%

20/10	Ocular Therapeutix Has 75% Success Probability for Axpaxli in Wet Age-Related Macular Degeneration, UBS Says	MT
20/10	EyePoint's DME Study Readout a Catalyst After wAMD Trial Misses Endpoint, RBC Says	MT

Evolution of the Average Target: EyePoint, Inc.

Evolution of the Target Price: EyePoint, Inc.

Changes in Analyst Recommendations: EyePoint, Inc.

3cd0cf849e90ecabdda0d43f6b4.egZdqvq-I6JUs6s3b4zyoklI_yWLelAgnY_0laKl-oU.Ml4FyJDQd9shw9FxOe6CkAQhmkfFShdsz8iWyv3Du_NCZRDsqfJv1Dzp5g~6730064feb25b57f73a5fd11cef86a7c

Analysts' recommendations: EyePoint, Inc.

20/10	Ocular Therapeutix Has 75% Success Probability for Axpaxli in Wet Age-Related Macular Degeneration, UBS Says	MT
20/10	EyePoint's DME Study Readout a Catalyst After wAMD Trial Misses Endpoint, RBC Says	MT
20/10	Laidlaw Downgrades EyePoint Pharmaceuticals to Hold From Buy	MT
20/10	JPMorgan Downgrades EyePoint Pharmaceuticals to Underweight From Neutral	MT
20/10	RBC Capital Adjusts Price Target on EyePoint Pharmaceuticals to $1 From $5, Keeps Sector Perform, Speculative Risk	MT
20/10	Mizuho Downgrades EyePoint Pharmaceuticals to Neutral From Outperform, Adjusts PT to $0.50 From $39	MT
19/10	Guggenheim Downgrades EyePoint to Neutral From Buy	MT
19/10	Jefferies Downgrades EyePoint Pharmaceuticals to Hold From Buy, $1 Price Target	MT
02/09	TD Cowen Downgrades EyePoint Pharmaceuticals to Hold From Buy, Adjusts PT to $4 From $20	MT
18/08	EyePoint Faces Regulatory Uncertainty After Lugano Trial Miss, RBC Capital Markets Says	MT
18/08	Chardan Downgrades EyePoint Pharmaceuticals to Neutral From Buy, Adjusts Price Target to $5 From $65	MT
18/08	RBC Downgrades EyePoint to Sector Perform From Outperform, Cuts Price Target to $5 From $37, Keeps Speculative Risk	MT
18/08	HC Wainwright Downgrades EyePoint Pharmaceuticals to Neutral From Buy	MT
17/08	JPMorgan Downgrades EyePoint Pharmaceuticals to Neutral From Overweight	MT
04/08	Ocular Therapeutix's NDA Plans for Axpaxli in Wet AMD Remain on Track, RBC Says	MT
29/07	Mizuho Raises Price Target on EyePoint Pharmaceuticals to $39 From $36, Keeps Outperform Rating	MT
16/07	Stifel Initiates EyePoint Pharmaceuticals at Buy With $40 Price Target	MT
01/07	Chardan Boosts Price Target on EyePoint Pharmaceuticals to $65 From $29, Keeps Buy Rating	MT
07/05	RBC Capital Adjusts EyePoint Pharmaceuticals PT to $37 From $39, Maintains Outperform Speculative-Risk Rating	MT
05/03	Chardan Raises Price Target on EyePoint Pharmaceuticals to $29 From $27, Keeps Buy Rating	MT
06/11	RBC Raises Price Target on EyePoint Pharmaceuticals to $39 From $28, Keeps Outperform, Speculative Risk	MT
15/25/15	Cooking oil, hot markets
14/25/14	Mizuho Adjusts Price Target on EyePoint Pharmaceuticals to $28 From $26, Maintains Outperform Rating	MT
17/25/17	RBC Capital Initiates EyePoint Pharmaceuticals at Outperform With $28 Price Target	MT
16/25/16	Mizuho Cuts Price Target on EyePoint Pharmaceuticals to $26 From $30, Keeps Outperform Rating	MT

More recommendations

Other Pharmaceuticals

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	EYEPOINT, INC.					+2,321.79%
	ELI LILLY AND COMPANY					-0.98%
	JOHNSON & JOHNSON					+2.27%
	ABBVIE INC.					-1.51%
	ROCHE HOLDING AG					-2.72%
	MERCK & CO., INC.					+6.9%
	NOVARTIS AG					-5.37%
	ASTRAZENECA PLC					+12.6%
	AMGEN INC.					-14.74%
	GILEAD SCIENCES, INC.					+0.12%
	Average					+231.84%
	Weighted average by Cap.					-0.16%